Redwood Pharma AB (publ) today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ).
Redwood Pharma has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on November 30, 2023. Until then, Erik Penser Bank AB will continue to act as Certified Adviser to the company.
For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ)
Tel: +46 (0) 70 232 29 29
About Redwood Pharma
Redwood Pharma AB (publ) (Nasdaq First North Growth Market: REDW) develops next-generation treatments for dry eye. More than 300 million people suffer from dry eyes and today’s standard treatment provides only temporary relief and may need to be applied more than ten times a day. Redwood Pharma’s programs are based on IntelliGel – a patented and unique formulation of polymers and water that has the consistency of a drop of water when dropped into the eye, where it immediately forms a viscous, protective and lubricating film that remains for a long time. The company is currently pursuing two development projects: RP501 as a readily available medical device for the first line treatment of dry eye, and the drug candidate RP101 that contains estrogen for the treatment of women who suffer from dry eye after menopause. The Company’s Certified Adviser is Carnegie Investment Bank AB (publ). For more information, visit www.redwoodpharma.com